SCHEMBL3837048

SCHEMBL3837048

Nc1nc(Cl)ccc1C(=O)c1ccccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
ALOX15 P16050 1/20 0.49
MAPT P10636 1/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
CDK5 Q00535 4/20 0.42
CDK5R1 Q15078 4/20 0.42
CDK2 P24941 4/20 0.40
GSK3B P49841 1/20 0.40
CDK1 P06493 1/20 0.38
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ESRRA P11474 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3839632 0.84 CDK2 (0.52) CES2CES1CDK2CDK1CDK4
SCHEMBL11279397 0.80 ALDH1A1 (0.43) ALDH1A1ALOX15MAPTCES2CES1
SCHEMBL3835745 0.78 MAPK14 (0.50) ALOX15CDK5CDK5R1CDK2CDK1
SCHEMBL3837825 0.76 LTA4H (0.43) MAPTCES2CES1CDK5CDK5R1
SCHEMBL28014540 0.76 ALDH1A1 (0.42) ALDH1A1ALOX15MAPTCES2CES1
SCHEMBL3836113 0.76 CDK1 (0.39) ALDH1A1MAPTCDK2CDK1CDK4
SCHEMBL30293901 0.75 CES2 (0.71) ALDH1A1ALOX15MAPTCES2CES1
SCHEMBL250099 0.75 CES2 (0.71) ALDH1A1ALOX15MAPTCES2CES1
SCHEMBL921731 0.74 MEN1 (0.51) ALDH1A1MAPTGAATDP1KMT2A
SCHEMBL29963527 0.73 ALDH1A1 (0.56) ALDH1A1ALOX15MAPTCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1980893-B Novel 2,6-diaminopyridine-3-one derivatives HOFFMANN LA ROCHE 2011-01-19 CN disclosed
EP-1771420-B1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
EP-1771420-B1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423051-B2 2,6-diaminopyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
CN-1980893-A Novel 2,6-diaminopyridine-3-one derivatives HOFFMANN LA ROCHE (CH) 2007-06-13 CN disclosed
EP-1771420-A1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-11 EP disclosed
US-20060014708-A1 2,6-Diaminopyridine derivatives BARTKOVITZ DAVID J 2006-01-19 US disclosed
WO-2006005548-A1 NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014708-A1 2,6-Diaminopyridine derivatives CDK2, CCNA2, CDK6 ALDH1A1 604/4885ALOX15 4005/4885MAPT 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.